Eli Lilly and Company
NYSE:LLYDrug Manufacturers - General
-$10.54 today
- Market cap
- $1.30T
- Beta
- 0.52
- P/E (TTM)
- 39.0
- EPS (TTM)
- $28.26
- Dividend yield
- 0.59%
Volume 2.58M
Average 3.19M
LLY Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Eli Lilly and CompanyNYSE: LLY
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin grows in line with its trailing trend
Q2 FY2026 selling, general & admin of $3.43B rose 24.6% year over year, behind the +25.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 16.9% from the prior quarter. Over 3 fiscal years it compounded at +22.3% a year.
Context
- Selling, general & admin amounted to 17.0% of revenue in FY2025, down 2.1 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 18 analysts of $18.58B (+67.5%) for the fiscal year ending Dec 2026, a step up from the +29.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $3.43B+16.9% QoQ
- Last fiscal yearDec 2025
- $11.09B+29.1% YoY
- LTMJun 2026
- $12.24B+25.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 11.09B USD
- Year-over-year change
- +29.1%
- 4-year CAGR
- +15.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.09B | +29.1% |
| FY2024 | 2024-12-31 | 8.59B | +23.8% |
| FY2023 | 2023-12-31 | 6.94B | +14.4% |
| FY2022 | 2022-12-31 | 6.07B | -1.2% |
| FY2021 | 2021-12-31 | 6.14B | — |
Selling, General & Admin vs competitors
How LLY compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +25.6% is the highest of 10, against a peer median of +1.8%.
- Selling, general & admin amounts to 15.4% of revenue for LLY, versus a peer median of 21.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 64.84B DKK | -9.7% | +11.5% | 19.7% | |
| LTM Sep 2026 | $25.5B USD | +11.0% | +5.4% | 25.7% | |
| LTM Sep 2026 | $20.52B USD | +0.5% | +4.5% | 33.0% | |
| LTM Sep 2026 | $15.19B USD | +8.7% | -2.8% | 23.0% | |
| LTM Jun 2026 | $13.72B USD | -1.7% | +0.3% | 21.5% | |
| LTM Jun 2026 | $13.13B USD | -0.1% | +3.0% | 23.6% | |
| LTM Jun 2026 | $12.24B USD | +25.6% | +22.3% | 15.4% | |
| LTM Jun 2026 | $10.39B USD | +10.8% | +3.5% | 15.7% | |
| LTM Jun 2026 | €9.82B EUR | +9.8% | +5.4% | 20.1% | |
| LTM Jun 2026 | $7B USD | +1.8% | +9.2% | 18.4% | |
| Peer median (excluding LLY) | — | +1.8% | +4.5% | 21.5% | |
Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 28.32B | 28.54B | 34.12B | 45.04B | 65.18B |
| Cost of Revenue | 7.31B | 6.63B | 7.08B | 8.42B | 11.05B |
| Gross Profit | 21.01B | 21.91B | 27.04B | 36.63B | 54.13B |
| Gross Margin | 74.2% | 76.8% | 79.2% | 81.3% | 83.0% |
| Research & Development | 6.93B | 7.19B | 9.31B | 10.99B | 13.34B |
| Selling, General & Admin | 6.14B | 6.07B | 6.94B | 8.59B | 11.09B |
| Operating Expenses | 13.07B | 13.26B | 16.25B | 19.59B | 24.43B |
| Depreciation & Amortization | 1.55B | 1.52B | 1.53B | 1.77B | 2B |
| EBITDA | 8.04B | 8.66B | 8.57B | 18.81B | 31.69B |
| EBITDA Margin | 28.4% | 30.3% | 25.1% | 41.8% | 48.6% |
| Operating Income | 7.93B | 8.65B | 10.79B | 17.04B | 29.7B |
| Operating Margin | 28.0% | 30.3% | 31.6% | 37.8% | 45.6% |
| Interest Income | 25.4M | 62.8M | 173.6M | 175.2M | 153.3M |
| Interest Expense | 339.8M | 331.6M | 485.9M | 780.6M | 795.3M |
| Other Income / Expenses | (1.78B) | (1.85B) | (4.23B) | (4.36B) | (3.97B) |
| Income Before Tax | 6.16B | 6.81B | 6.55B | 12.68B | 25.73B |
| Pre-Tax Margin | 21.7% | 23.8% | 19.2% | 28.2% | 39.5% |
| Income Tax Expense | 573.8M | 561.6M | 1.31B | 2.09B | 5.09B |
| Net Income | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B |
| Net Margin | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
| EPS (Basic) | 5.85 | 6.57 | 5.83 | 11.76 | 23.07 |
| EPS (Diluted) | 5.85 | 6.57 | 5.80 | 11.71 | 22.95 |
| Weighted Avg Shares | 953.65M | 950.18M | 899.38M | 900.61M | 898M |
| Weighted Avg Shares (Diluted) | 953.65M | 950.18M | 903.28M | 904.06M | 898M |
Eli Lilly and Company
NYSE:LLY
Intrinsic Alpha fair value
Locked
Current Price
$1,382.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.